Context Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
CNTX$0.19-6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(36,123,615) | $(26,725,104) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Acquired in-process research and development charge | 2,000,000 | 14,750,000 |
| Share-based compensation expense | 1,331,080 | 841,867 |
| Depreciation and amortization expense | 16,251 | 10,881 |
| Reduction in the carrying amount of operating lease right-of-use asset | 108,406 | 41,822 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,107,686 | (1,868,776) |
| Accounts payable | 1,095,967 | (946,096) |
| Accrued expenses and other current liabilities | 4,186,161 | (619,770) |
| Operating lease liability | (107,316) | (41,258) |
| Cash used in operating activities | (26,385,380) | (14,556,434) |
| Cash flows from investing activities: | ||
| Acquired in-process research and development | (2,000,000) | (14,750,000) |
| Purchase of property and equipment | (33,948) | (7,316) |
| Cash used in investing activities | (2,033,948) | (14,757,316) |
| Cash flows from financing activities: | ||
| Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs | — | 94,758,747 |
| Payment of offering costs from the sale of common stock from ATM facility | (15,268) | — |
| Proceeds from the sale of common stock from ATM facility, net | — | 14,535,000 |
| Cash (used in) provided by financing activities | (15,268) | 109,293,747 |
| Net (decrease) increase in cash and cash equivalents | (28,434,596) | 79,979,997 |
| Cash and cash equivalents at beginning of year | 94,429,824 | 14,449,827 |
| Cash and cash equivalents at end of year | $65,995,228 | $94,429,824 |
| Supplemental disclosure of non-cash activities: | ||
| Cashless exercise of prefunded warrants from private placement | $2,175 | $— |
| Unpaid offering costs in Accounts payable | $— | $15,268 |
| Right-of-use asset acquired under operating lease | $— | $260,638 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.